PATIENT CHARACTERISTICS AND TREATMENT ADHERENCE AMONG PATIENTS TREATED WITH DELAYED-RELEASE DIMETHYL FUMARATE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN ISRAEL

被引：0
|
作者：
Desai, U. [1 ]
Huang, M. [2 ]
Kirson, N. Y. [1 ]
King, S. [1 ]
Hellstern, M. [1 ]
Schonfeld, S. [1 ]
Birnbaum, H. G. [1 ]
Lee, A. [2 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Biogen, Cambridge, MA USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND45
引用
收藏
页码：A195 / A195
页数：1
相关论文
共 50 条
  • [21] Clinical efficacy of delayed-release dimethyl fumarate in Hispanic patients with relapsing-remitting multiple sclerosis: integrated analysis of define and confirm
    Hernandez, L.
    Fox, R. J.
    Gold, R.
    Phillips, J. T.
    Okwuokeny, M.
    Zhang, A.
    Rana, J.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E306 - E306
  • [22] A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis
    Allan, Michelle
    Grant, Lindsay
    NEUROLOGY AND THERAPY, 2020, 9 (01) : 85 - 92
  • [23] The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada
    Dorman, Emily
    Kansal, Anuraag R.
    Sarda, Sujata
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (12) : 1085 - 1091
  • [24] Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis (RRMS) in "non-responders'' to prior treatment with interferon beta
    Fernandez, O.
    Giovannoni, G.
    Fox, R. J.
    Gold, R.
    Phillips, J. T.
    Yang, M.
    Zhang, A.
    Kurukulasuriya, N. C.
    JOURNAL OF NEUROLOGY, 2014, 261 : S19 - S20
  • [25] Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis (RRMS) in "non-responders" to prior treatment with interferon beta
    Fernandez, O.
    Giovannoni, G.
    Fox, R. J.
    Gold, R.
    Phillips, J. T.
    Yang, M.
    Zhang, A.
    Kurukulasuriya, N. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 25 - 25
  • [26] Delayed-release Dimethyl Fumarate Demonstrates Sustained Efficacy over Nine Years in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis
    Gold, Ralf
    Giovannoni, Gavin
    Phillips, J. Theodore
    Bar-Or, Amit
    Fox, Robert J.
    Chen, Chongshu
    Miller, Catherine
    NEUROLOGY, 2019, 92 (15)
  • [27] Delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis - findings from a real-world setting in Russian Federation
    Davydovskaya, M.
    Pozhidaeva, N.
    Dubchenko, E.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 934 - 935
  • [28] Safety of Delayed-release Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis Patients from ENDORSE: Seven-Year Interim Results
    Pozzilli, Carlo
    Phillips, J. Theodore
    Fox, Robert J.
    Prada, Claudia
    Yang, Lili
    Taylor, Catherine
    Fay, Monica
    NEUROLOGY, 2017, 88
  • [29] Delayed-release dimethyl fumarate demonstrates sustained efficacy over nine years in newly diagnosed patients with relapsing-remitting multiple sclerosis
    Gold, R.
    Giovannoni, G.
    Phillips, J. T.
    Bar-Or, A.
    Fox, R. J.
    Chen, C.
    Miller, C.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 498 - 499
  • [30] Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States
    Mauskopf, Josephine
    Fay, Monica
    Iyer, Ravi
    Sarda, Sujata
    Livingston, Terrie
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (04) : 432 - 442
12345